# Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV

> **NCT02016924** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Gilead Sciences** · enrollment: 133 (actual)

## Conditions studied

- Acquired Immune Deficiency Syndrome (AIDS)
- HIV Infections

## Interventions

- **DRUG:** ATV
- **DRUG:** DRV
- **DRUG:** Cobicistat
- **DRUG:** BR
- **DRUG:** F/TAF
- **DRUG:** LPV/r
- **DRUG:** Third Unboosted Drug
- **DRUG:** Cobicistat TOS
- **DRUG:** F/TAF TOS

## Key facts

- **NCT ID:** NCT02016924
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-01-16
- **Primary completion:** 2025-06-13
- **Final completion:** 2027-03
- **Target enrollment:** 133 (ACTUAL)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02016924

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02016924, "Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02016924. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*